Literature DB >> 7609182

Postoperative hospitalization of children undergoing cross-trigonal ureteroneocystostomy.

A C McCool1, D B Joseph.   

Abstract

The hospital records of 145 girls and 41 boys who had undergone ureteroneocystostomy for vesicoureteral reflux were retrospectively reviewed to determine the duration of urethral catheterization and postoperative hospitalization. Children with a complicated urological history or the need for ureteral tapering and stent placement were excluded. The trend in urethral catheter removal was from 2.71 days postoperatively during the first year of the study to 1.18 days during the last year. Postoperative hospitalization decreased from 4 to 2 days. It is now routine practice to remove the urethral catheter on the first postoperative day and discharge the patient from the hospital on the second day. The surgical resolution of reflux was 96%.

Entities:  

Mesh:

Year:  1995        PMID: 7609182     DOI: 10.1097/00005392-199508000-00125

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Current surgical management of vesicoureteral reflux.

Authors:  Minki Baek; Kyung Do Kim
Journal:  Korean J Urol       Date:  2013-11-06

2.  The effect of surgeon volume and hospital characteristics on in-hospital outcome after ureteral reimplantation in children.

Authors:  Rian J Dickstein; Joseph G Barone; J G Liao; Randall S Burd
Journal:  Pediatr Surg Int       Date:  2006-04-12       Impact factor: 1.827

3.  Bladder spasm in children after surgery for ureteric reimplantation.

Authors:  D Gillies; L Lane; D Murrell; R Cohen
Journal:  Pediatr Surg Int       Date:  2003-11-27       Impact factor: 1.827

4.  Comparative Clinical Study Between Modified Ureteral Orthotopic Reimplantation and Cohen Method Under Pneumovesicum in Pediatric Patients With Hydroureteronephrosis.

Authors:  Jiaming Chang; Qiangye Zhang; Peimin Hou; Dongming Wang; Aiwu Li; Xiaona Lv
Journal:  Front Pediatr       Date:  2020-03-06       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.